Clinical trials: Ebola Virus Disease
Ebola Disease
A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine
A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults Aged Between 18 and 50 years in…
- Trial name
- NCT02575456
- Testing
- Ebola Vaccine
- Where
- Sierra Leone
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ebola Virus Disease, Marburg Virus Disease
Evaluating an Ebola and a Marburg Vaccine in Uganda
This study will test two new vaccines, one for Ebola and one for Marburg virus, to see if they are safe, if they have side effects, and if they create an immune response in people who receive them.
- Trial name
- NCT00997607
- Testing
- Ebola vaccine, Marburg vaccine
- Where
- Uganda
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola
A Study in Tanzania of a New Vaccine Against Two Types of Ebola
An open label, first in human, non-randomised, dose escalation, single centre, phase Ib clinical trial
- Trial name
- NCT05301504
- Testing
- ChAdOx1 biEBOV
- Where
- Tanzania
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda
Screen participants attending 11 healthcare facilities in Mubende District for psychological distress using the locally validated Luganda or English version of the WHO- Self Report Questionnaire (SRQ-20).
- Trial name
- Ebola+D (NCT06093646)
- Testing
- Ebola+D intervention
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Ebola, Post-Acute Ebola Syndrome
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Background: Ebola virus disease (EVD) causes fever, vomiting, and diarrhea, and may cause internal bleeding. It is often fatal. EVD may also damage the brain and nervous system.
- Trial name
- NCT06811129
- Where
- Liberia
- Volunteers
- 328 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Healthy
Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers
Background: Ebola is a virus that can spread quickly and causes serious disease. It is currently causing an outbreak in West Africa. There are no approved treatments for Ebola.
- Trial name
- NCT02389192
- Testing
- ZMAPP
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
- Trial name
- NCT02041715
- Testing
- TKM-100802 for Injection
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Ebola
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3…
- Trial name
- NCT04228783
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease
Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.
- Trial name
- NCT04711356
- Testing
- Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
- Where
- Sierra Leone
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Ebola Hemorrhagic Fever
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.
- Trial name
- NCT01353027
- Testing
- AVI-6002
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Influenza, Severe Acute Respiratory Distress Syndrome
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
This study will examine the safety of an experimental medication called Poly-ICLC, developed for preventing or reducing the severity of infections from influenza and other viruses acquired through the nose, mouth and lungs.
- Conditions
- Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola
- Trial name
- NCT00646152
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease, COVID-19
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases.
- Trial name
- NCT06587503
- Testing
- BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Hemorrhagic Fever, Ebola
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
This is an emergency, phase 2/3, open-label, non-randomized, clinical trial that will evaluate Convalescent Plasma (CP) added to standardized supportive care (SC) in patients with confirmed Ebola Virus Disease (EVD).
- Trial name
- Ebola-Tx (NCT02342171)
- Testing
- Convalescent Plasma
- Where
- Guinea
- Volunteers
- 606 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Virus Disease
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.
- Trial name
- NCT04152486
- Testing
- Ad26.ZEBOV, MVA-BN-Filo vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,426 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Ebola Virus Disease
Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
A Phase I/II Pilot Clinical Trial to Evaluate the Efficacy and Safety of Ebola Virus Disease (EVD) Convalescent Plasma (ECP) for treatment of EVD.
- Trial name
- EVD001 (NCT02333578)
- Testing
- Convalescent Plasma Treatment
- Where
- Liberia
- Volunteers
- 70 people
- Sponsor
- Clinical Research Management, Inc.
Acute Ebola Virus Disease
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
- Trial name
- NCT02295501
- Testing
- INTERCEPT Plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cerus Corporation
Prevention of Ebola Infection
Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults.
- Trial name
- NCT02503202
- Testing
- V920 Consistency Lot A, V920 Consistency Lot B, V920 Consistency Lot C
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Immune Response
Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers
During the previous Ebola virus disease (EVD) outbreaks, the institute National de Recherche Biomédicale (INRB) and other institutional's staff in Democratic Republic of the Congo (DRC) got vaccinated with the rVSV-ZEBOV vaccine.
- Trial name
- EBOSURV (NCT05313139)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola, HIV/AIDS
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Ebola and HIV are found predominately in the same regions of the world and countries in sub-Saharan Africa are most affected by both diseases. For Ebola, no approved therapies exist.
- Trial name
- RemTLAR (NCT04385719)
- Testing
- Remdesivir
- Where
- Uganda
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Makerere University
Ebola Virus Disease
Multiple Treatments for Ebola Virus Disease (EVD)
The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)
- Trial name
- NCT02380625
- Testing
- Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan
- Volunteers
- 150 people
- Sponsor
- Clinical Research Management, Inc.